| Trial ID: | L3557 |
| Source ID: | NCT00368368
|
| Associated Drug: |
Gk Activator (2)
|
| Title: |
A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: GK Activator (2)
|
| Outcome Measures: |
Primary: Vital signs, adverse events, laboratory parameters., Throughout study | Secondary: AUC, Tmax, Cmax, T1/2, CL/F, CLR for GK Activator (2) and metabolite. Glucose Cmax and Cmin, and percentage decrease in glucose from baseline., Throughout study.
|
| Sponsor/Collaborators: |
Sponsor: Hoffmann-La Roche
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
5
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-01
|
| Completion Date: |
2007-08
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-02
|
| Locations: |
Cypress, California, 90630, United States|Austin, Texas, 78758, United States|Dallas, Texas, 75247, United States|San Antonio, Texas, 78229, United States|Bratislava, 833 01, Slovakia
|
| URL: |
https://clinicaltrials.gov/show/NCT00368368
|
